Objective To compare the clinical effects of roxadustat and recombinant human erythropoietin(rHuEPO)in treatment of maintenance hemodialysis patients with renal anemia.Meth-ods From January 2021 to December 2023,100 patients with renal anemia undergoing maintenance hemodialysis admitted to Northern Jiangsu People's Hospital Affiliated to Yangzhou University were se-lected as study subjects.Based on different treatment approaches,they were divided into control group(n=50)and observation group(n=50).Both groups received iron supplementation therapy,with the control group using recombinant human erythropoietin(rHuEPO)and the observation group using roxa-dustat.Anemia indicators,iron metabolism indicators,and the incidence of adverse reactions were ob-served and compared between the two groups.Results Before treatment,there was no statistically sig-nificant difference in the indicators between the two groups(P＞0.05).After treatment,the indicators of both groups improved compared to before treatment,and the indicators of the observation group were superior to those of the control group(P＜0.05).The incidence of adverse reactions in the observation group was 2.00％,which was lower than 16.00％in the control group(P＜0.05).Conclusion Com-pared with rHuEPO,roxadustat can significantly improve anemia and iron metabolism,with high safety and application value.
关键词
罗沙司他/重组人促红细胞生成素/维持性血液透析/肾性贫血/铁代谢/不良反应
Key words
roxadustat/recombinant human erythropoietin/maintenance hemodialysis/renal anemia/iron metabolism/adverse reactions
维普
万方数据